Case Report

Unexpected Genotype in a Non-Transfusion Dependent Thalassemia Family

Cristina Curcioa, d, Valentina Giannonea, Elena Benzoni a, Claudia Cesaretti b, Elena Cassinerioc, Manuela Seia, Giovanna Graziaide

Abstract

Non-transfusion dependent thalassemia (NTDT) is an inherited hemoglobin disorder characterized by an α/non-α globin chain imbalance of variable severity, resulting in a wide spectrum of clinical manifestations. The coinheritance of additional α genes with a beta-thalassemia heterozygous mutation has a well-known negative effect. Triplication or quadruplication alone are mostly found by chance, but the coinheritance with β mutations can worsen the very mild anemia to a more severe hematological and clinical phenotype causing NTDT, depending on the severity of beta mutations. We describe a case of a 38-year-old β-thalassemia trait, pregnant woman at 33 weeks of gestation with supernumerary α-globin genes and two β-globin defects.

Keywords: Non-transfusion dependent thalassemia; Supernumerary α-globin genes; α and β-globin defects coinheritance; Genetic counselling

Introduction

Non-transfusion dependent thalassemia (NTDT) [1] is an inherited hemoglobin disorder characterized by an α/non-α globin chain imbalance of variable severity, resulting in a wide spectrum of clinical manifestations. Phenotype reflects the genetic heterogeneity which depends on different molecular mechanisms, the most important of which are: 1) The coinheritance of two β-globin defects (homozygous or compound heterozygous for β0 and β+ mutations) with relative excess of unmatched alpha chains [2, 3]; 2) The imbalance of α/non-α globin-chain synthesis ratio due to the coinheritance of a β mutation with supernumerary α-globin genes, resulting in an absolute excess of unmatched α chains [4-8]. Excess α-globin chains precipitate damaging erythroid membrane structures and increase destruction of erythroid cells by peripheral hemolysis and premature destruction of precursors in the bone marrow, resulting in anemia and ineffective erythropoiesis [2]. The mechanism of α-globin gene copy number alterations is based on a misalignment and reciprocal crossover involving α-globin gene cluster, due to the high homology of HBA1 and HBA2 genes. This recombinant event generates both alleles with a common α deletion (3.7 kb I, II, III, 4.2 kb) and alleles with three active α-globin genes (aaaanti-α3.7; aaaaanti-α4.2) [8].

A second unequal crossover within a normal chromosome and a chromosome bearing the triplication, causes the quadruplication (aaaaanti-α3.7; aaaaanti-α4.2) of α-globin genes [9]. During evolution these rearranged chromosomes undergo positive selection in the population [10]. The negative effect of additional α genes coinherence with a beta-thalassemia heterozygous mutation is well known [2, 11].

Case Report

We describe a case of a 38-year-old β-thalassemia trait, pregnant woman at 33 weeks of gestation referred to the Rare Diseases Centre of Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy, for severe anemia requiring blood transfusion support.

Her anamnesis was not clinically relevant before pregnancy; she referred an average hemoglobin (Hb) level of 9.5 g/dL, the clinical picture showed normal spleen and liver size. To better explain the worsening of Hb level during pregnancy, hematological and hemoglobin patterns were assessed, showing Hb 7.2 g/dL, red blood cell (RBC) 3.44 × 10⁶/mm³, mean corpuscular volume (MCV) 70.1 fl, HBA2 4.9%, HbF 3.8% (high-performance liquid chromatography (HPLC) Biorad D100, Biorad Laboratories, Hercules, CA, USA), and globin genes molecular analysis was performed (BigDye Terminator Cycle Sequencing Ready Reaction Kit v.1.1).

DNA sequencing of β-globin gene revealed β0 IVS-I-110 (c.93-21G>A) and β+/+ IVS-II-726 (c.316-125A>G) mutations; the second mutation is very rare and was reported in...
Database of Human Hemoglobin Variants and Thalassemia mutations (HbVar Database http://globin.bx.psu.edu/hbvar/menu.html) both as β+ and βsilent thalassemia mutation [12, 13]. HBB gene analysis was inconclusive to solve the proband clinical picture. An α-globin genes cluster study with multiplex ligation-dependent probe amplification (MLPA) method was performed according to the manufacturer’s instructions (SALSA MLPA kit P140B2 HBA; MRC-Holland, Amsterdam, The Netherlands). MLPA probe set resulted in a complex rearrangement of HBA1 and HBA2 gene spanning from probe HBA2-up (373) to HBA1-intr.2 (165) (Fig. 1) with a different ratio which could be interpreted as a combination of α4.2 quadruplication and α3.7 triplication, resulting in seven active genes.

To study the allelic segregations, family hematological and hemoglobin pattern were investigated (Table 1). The mother and brother’s hematological phenotype was consistent with β-thalassemia carrier, while the father’s was normal. Besides the patient, only the mother showed slightly higher HbF levels, resulting in heterozygosity of -158Gγ (C→T) Xmn1 polymorphism detected by sequencing analysis of gamma globin genes; the same alteration was found in the proband. Even if the HbF level was normal in the father and the brother, gamma-globin gene analysis was performed; the c.227T>C in HBG1 globin gene (HbF-Sardinia) was identified only in the father, known to be associated with increase of 10% of the total HbF.

HBB direct sequencing and MLPA analysis of the α-globin gene cluster revealed that the mother was a carrier of β+ IVS-I-110 associated with a α4.2 quadruplication, while the father was a carrier of β+ IVS-II-726 and α3.7 triplication. Molecular analysis was also extended to the proband’s brother and showed the presence of β+ IVS-I-110 in heterozygous state and α3.7 triplication. All the relatives were asymptomatic.

Triplication or quadruplication alone are mostly found by chance, but the coinheritance with β mutations could worsen the very mild anemia to a more severe hematological and clinical phenotype causing NTDT, depending on the severity of beta mutations [4]. Although HbF is usually slightly increased in these molecular patterns, we underline that in this case HbF levels are not significant and are sustained by gamma-globin genes alterations.

In the proband’s partner HBB gene was studied by sequencing analysis and HBA cluster by MLPA technique, resulting both negative.

**Discussion**

To define reproductive risk in these cases, hematological screening and molecular analysis of beta-globin mutations and α-globin genes rearrangement are strongly recommended in the partner, even if he has a normal hematologic profile, to exclude the presence of genetic alterations potentially worsening offspring’s hematologic phenotype. Although the partner had no evidence of hemoglobin disorder, the couple still had a reproductive risk of having offspring with NTDT: specifically all their children would inherit one β mutation in association with supernumerary α genes. Therefore, the clinical picture of
Unexpected Genotype in an NTDT Family

J Med Cases. 2020;11(4):90-93

the offspring could vary from a very mild form, likely asymptomatic, deriving from the coinheritance of $\beta^{+/-}$ IVS-II-726 and $\alpha\alpha\alpha\alpha$ anti-$\alpha_{3.7}$ triplication to a mild/moderate form, if the child inherits the $\beta^{+}$ IVS-I-110 with $\alpha\alpha\alpha\alpha$ anti-$\alpha_{4.2}$ quadruplication. In this molecular pattern, even if the reproductive risk is 100%, all the possible genotype combinations result generally in mild form of NTDT, without major or early onset complications.

Acknowledgments

The authors would like to acknowledge Fondazione G. e D. De Marchi Onlus, Milan, Italy for supporting to this work.

Financial Disclosure

None to declare.

Conflict of Interest

The authors declare no conflict of interest.

Informed Consent

All subjects signed the informed consent form before blood sampling.

Adverse Events

The authors declare that no adverse events occurred during the course of the study.

Author Contributions

C. Curcio and G. Graziadei analyzed the data and wrote the paper. V. Giannone and E. Benzoni performed molecular analysis and interpretation of data. M. Seia contributed in proofreading and language editing. C. Cesaretti performed genetic counseling. E. Cassinerio performed evaluation of hematological and biochemical parameters.

Data Availability

The authors declare that data supporting the findings of this study are available within the article.

References

1. Weatherall DJ. The definition and epidemiology of non-transfusion-dependent thalassemia. Blood Rev. 2012;26(Suppl 1):S3-6.
2. Harteveld CL, Refaldi C, Cassinerio E, Cappellini MD, Giordano PC. Segmental duplications involving the alpha-globin gene cluster are causing beta-thalassemia intermedia phenotypes in beta-thalassemia heterozygous patients. Blood Cells Mol Dis. 2008;40(3):312-316.
3. Sullivan KM, Anasetti C, Horowitz M, Rowlings PA, Petersdorf EW, Martin PJ, Clift RA, et al. Unrelated and HLA-nonidentical related donor marrow transplantation

Table 1. Comparison Between Proband’s and Relatives’ Hematological and HPLC Data

|                  | Proband        | Mother         | Father         | Brother        | Partner        |
|------------------|----------------|----------------|----------------|----------------|----------------|
| RBC              | $3.44 \times 10^{12}$/L | $5.90 \times 10^{12}$/L | $4.53 \times 10^{12}$/L | $5.77 \times 10^{12}$/L | $4.68 \times 10^{12}$/L |
| Hb               | 7.2 g/dL       | 11.3 g/dL      | 13.9 g/dL      | 12.2 g/dL      | 15.7 g/dL      |
| HCT              | 24.1%          | 36.5%          | 39.6%          | 38.8%          | n.d.           |
| MCV              | 70.1 fl        | 61.9 fl        | 87.4 fl        | 67.2 fl        | 87.7 fl        |
| MCH              | 20.9 pg        | 19.2 pg        | 30.7 pg        | 21.1 pg        | n.d.           |
| MCHC             | 29.9 g/dL      | 31.0 g/dL      | 35.1 g/dL      | 31.4 g/dL      | n.d.           |
| RDW              | 24.9%          | 19.5%          | 12.0%          | 16.9%          | n.d.           |
| Reticulocytes    | 0.205 $\times 10^{10}$/L | 0.158 $\times 10^{12}$/L | 0.087 $\times 10^{12}$/L | 0.144 $\times 10^{12}$/L | n.d.           |
| Bilirubin total  | 1.52 mg/dL     | 1.12 mg/dL     | 1.09 mg/dL     | 1.60 mg/dL     | n.d.           |
| LDH              | 450 U/L        | 205 U/L        | 187 U/L        | 160 U/L        | n.d.           |
| Haptoglobin      | n.d.           | 32 mg/dL       | 118 mg/dL      | 67 mg/dL       | n.d.           |
| Iron             | 416 µg/dL      | 125 µg/dL      | 91 µg/dL       | 164 µg/dL      | n.d.           |
| Ferritin         | 326 µg/L       | 604 µg/L       | 165 µg/L       | 269 µg/L       | n.d.           |
| Transferrin      | 347 mg/dL      | 238 mg/dL      | 248 mg/dL      | 261 mg/dL      | n.d.           |
| HBA2             | 4.9 %          | 4.5%           | 2.7%           | 4.8%           | 2.3%           |
| HbF              | 3.8%           | 1.3%           | 0.9%           | 0.9%           | 0.9%           |
| HbX              | n.d.           | n.d.           | n.d.           | n.d.           | n.d.           |

HPLC: high-performance liquid chromatography; RBC: red blood cell; Hb: hemoglobin; HCT: hematocrit; MCV: mean corpuscular volume; MCH: mean corpuscular hemoglobin; MCHC: mean corpuscular hemoglobin concentration; RDW: red blood cells distribution width; LDH: lactate dehydrogenase; n.d.: no data.
for thalassemia and leukemia. A combined report from the seattle marrow transplant team and the international bone marrow transplant registry. Ann N Y Acad Sci. 1998;850:312-324.

4. Liu S, Jiang H, Wu MY, Zhang YL, Li DZ. Thalassemia intermedia caused by 16p13.3 sectional duplication in a beta-thalassemia heterozygous child. Pediatr Hematol Oncol. 2015;32(5):349-353.

5. Wainscoat JS, Kanavakis E, Wood WG, Letsky EA, Huehns ER, Marsh GW, Higgs DR, et al. Thalassaemia intermedia in Cyprus: the interaction of alpha and beta thalassaemia. Br J Haematol. 1983;53(3):411-416.

6. Thein SL, Hesketh C, Wallace RB, Weatherall DJ. The molecular basis of thalassaemia major and thalassaemia intermedia in Asian Indians: application to prenatal diagnosis. Br J Haematol. 1988;70(2):225-231.

7. Beris P, Solenthaler M, Deutsch S, Darbellay R, Tobler A, Bochaton-Pialat ML, Gabbiani G. Severe inclusion body beta-thalassaemia with anaemia in a patient double heterozygous for beta(0)-thalassaemia and quadruplicated alpha-globin gene arrangement of the anti-4.2 type. Br J Haematol. 1999;105(4):1074-1080.

8. Sollaino MC, Paglietti ME, Perseu L, Giagu N, Loi D, Galanello R. Association of alpha globin gene quadruplication and heterozygous beta thalassemia in patients with thalassemia intermedia. Haematologica. 2009;94(10):1445-1448.

9. Gu YC, Landman H, Huisman TH. Two different quadruplicated alpha globin gene arrangements. Br J Haematol. 1987;66(2):245-250.

10. Higgs DR, Hill AV, Bowden DK, Weatherall DJ, Clegg JB. Independent recombination events between the duplicated human alpha globin genes; implications for their concerted evolution. Nucleic Acids Res. 1984;12(18):6965-6977.

11. Graziaedi G, Refaldi C, Barcellini W, Cesaretti C, Cassinerio E, Musallam KM, Cappellini MD. Does absolute excess of alpha chains compromise the benefit of splenectomy in patients with thalassemia intermedia? Haematologica. 2012;97(1):151-153.

12. Patrinos GP, Giardine B, Riemer C, Miller W, Chui DH, Anagnou NP, Wajcman H, et al. Improvements in the HbVar database of human hemoglobin variants and thalassemia mutations for population and sequence variation studies. Nucleic Acids Res. 2004;32(Database issue):D537-541.

13. Agouti I, Bennani M, Nezri M, Levy N, Badens C. Beta-thalassemia intermedia due to two novel mutations in the promoter region of the beta-globin gene. Eur J Haematol. 2008;80(4):346-350.